The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time.

Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity ... 1.5mg dulaglutide dose. From a mean baseline body weight of 95 ...